

Advances in Cell and Gene Therapies Symposium

Program

Monday 13th May 2024, 9am-3.45pm. Melbourne Brain Centre Auditorium, 30 Royal Parade, Parkville

Presenter	Topic	Time
Prof Clare Parish Deputy Director, Florey Institute	Welcome	9.00
Prof Sir John Savill Executive Director, MACH	Introduction to Melbourne Academic Centre for Health (MACH)	9.05
Session 1: Case studies - what can we learn from them?		9.15
Chair: A/Prof Jane Oliaro , Chief Scientist, Centre of Excellence in Cellular Immunotherapy, Peter MacCallum Cancer Centre		
Prof Simon Harrison Head of Haematology, Peter MacCallum Cancer Centre	Governance and clinical aspects of CAR-T cell delivery	9.20
Prof Simon Barry VP CAR-T Manufacturing Research and Development, Carina Biotech	Carina Biotech: Australian research to clinical trial	9.40
A/Prof Lauren Ayton Clinician Scientist, University of Melbourne and Centre for Eye Research Australia (CERA)	CERA research translation and clinical implementation of Cell/Gene therapies	10.00
Prof Andrew Davidson Medical Director, Melbourne Children's Trials Centre (MCTC)	Supporting the development and implementation of Cell/Gene therapy clinical trials at MCTC	10.20
Break		10.40
Session 2: Research to clinic to commercialisation		11.15
Chair: A/Prof Dominic Wall , Executive Director Business Ventures, Peter MacCallum Cancer Centre and Chief Scientific Officer, Cell Therapies		
Gerry McKiernan Director and Principle Consultant, Increment4	Quality system considerations: research, translation, manufacturing and the clinic	11.20



Dr Melanie Domingues Project Portfolio Manager, Cell Therapies	Navigating translation: Essential considerations in manufacturing process design and analytical testing from process development to clinical trial and commercialisation	11.40
Prof Alan Trounson CEO and President, Cartherics	Moving from transplant to pluripotent stem cell derived cellular therapies	12.00
Dr Ellen Otte Director, Cell Culture and Cell and Gene Therapy Development, CSL	Are you building a platform or a product? Implications around process development, product definition and indication selection	12.20
Lunch		12.40
Session 3: Synergising local initiatives in cell and gene therapy training and workforce development		13.40
3a) Synergising clinical needs in training and workforce development - clinical initiatives and panel discussion		
Chairs: Prof Melissa Little , Chief Scientist, Murdoch Children's Research Institute and CEO, Novo Nordisk Foundation Centre for Stem Cell Medicine Prof Christine Wells , Director, University of Melbourne Centre for Stem Cell Systems and Co-Chair MACH Cell and Gene Therapies committee		
Dr Ian Woodcock Paediatric Neurologist, Royal Children's Hospital (RCH)	Initiatives for training and workforce development: RCH and MCRI	13.45
Prof Keith Martin Managing Director, Centre for Eye Research Australia (CERA)	Initiatives for training and workforce development: CERA	13.50
Dr Tom Loudovaris Islet Transplant Manager, St Vincent's Institute of Medical Research (SVI)	Initiatives for training and workforce development: SVI Transplant Facility	13.55
A/Prof Jane Oliaro Chief Scientist, Centre of Excellence in Cellular Immunotherapy, Peter MacCallum Cancer Centre	Initiatives for training and workforce development: Centre of Excellence in Cellular Immunotherapy	14.00
Panel discussion		14.05
Break		14.40
Session 3 continued		14.50

3b) Synergising process development and manufacturing needs in training and workforce development – panel discussion

Chairs:

Prof Alice Pébay, Chief Scientific Officer, CCRM Australia and NHMRC Senior Principal Research Fellow, University of Melbourne and Royal Melbourne Hospital

Prof Christine Wells, Director, University of Melbourne Centre for Stem Cell Systems and Co-Chair MACH Cell and Gene Therapies committee

Panel discussion

14.55

David Kneen

CEO, Celleo Biotech

Dr Jennifer Hollands

Government and Academic Liaison, Cell Therapies

A/Prof Jennifer Short

Director, Monash Centre for Advanced mRNA Medicines Manufacturing and Workforce Training

Dr Ellen Otte

Director, Cell culture and cell and gene therapy development, CSL

Prof Christine Wells

Director, University of Melbourne Centre for Stem Cell Systems

Closing remarks

15.40

With thanks to our generous sponsors:

[CSL](#)

[University of Melbourne Department of Anatomy and Physiology](#)

[University of Melbourne School of Biomedical Sciences](#)



This event was organised on behalf of the [MACH Cell and Gene Therapies committee](#).